European Primary Care Cardiovascular Society

COVID-19

2022 ACC expert consensus pathway on cardiovascular sequelae of COVID-19

News - Mar. 24, 2022

The expert consensus pathway provides recommendations for the evaluation and management of adults with myocarditis and long COVID following COVID-19 infection.

Increased risk of long-term CV outcomes after COVID-19

Literature - Feb. 15, 2022 - Xie Y et al. - Nat Med. 2022

A study shows that individuals in the post-acute phase of COVID-19 exhibited increased risks and 12-month burdens of incident CV diseases, compared to individuals with no evidence of SARA-CoV-2 infection.

Signs of affection of multi-organ systems after recovery from mild to moderate COVID-19

Literature - Jan. 20, 2022 - Petersen EL, et al. - Eur Heart J 2021

A cross-sectional study showed subclinical signs of affection of the pulmonary, cardiac, coagulation and renal systems in mainly non-hospitalized individuals who had mild to moderate SARS-CoV-2 infection ~9 months ago.

After COVID-19 hospitalization extended thromboprophylaxis with DOAC improves outcomes

Literature - Jan. 11, 2022 - Ramacciotti E, et al. - Lancet 2022

The MICHELLE trial shows that extended post-discharge thromboprophylaxis with the DOAC rivaroxaban for 35 days improved clinical outcomes compared to no anticoagulation in patients with high risk of thromboembolism who were hospitalized due to COVID-19.

ESC Guidance document on diagnosis and treatment of CVD during the COVID-19 pandemic

News - Dec. 6, 2021

The Task Force for the management of COVID-19 of the ESC has published two documents that are aimed to provide guidance for the diagnosis and management of CVD during the COVID-19 pandemic.

Highly-purified icosapent ethyl does not reduce clinical outcomes in non-hospitalized COVID-19 patients

News - Nov. 15, 2021

AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.

No improvement of outcomes with therapeutic-dose of heparin in critically ill COVID-19 patients

Literature - Aug. 16, 2021 - The REMAP-CAP, ACTIV-4a, and ATTACC Investigators, et al. - NEJM 2021
In an open-label, multiplatform, randomized trial, therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin did not improve clinical outcomes compared to usual-care pharmacologic thromboprophylaxis in critically ill COVID-19 patients.

In an open-label, multiplatform, randomized trial, therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin did not improve clinical outcomes compared to usual-care pharmacologic thromboprophylaxis in critically ill COVID-19 patients.

COVID-19 vaccine-induced atypical thrombosis and thrombocytopenia in some individuals

Literature - Apr. 26, 2021 - Scully M, et al. - N Engl J Med. 2021 Apr 16.

This study described the clinical features of 23 patients who after receiving the first dose of ChAdOx1 nCoV-19 vaccine developed atypical platelet factor 4 (PF4)-dependent thrombosis and/or thrombocytopenia that resembles heparin-induced thrombocytopenia.

Some cases after COVID-19 vaccination show clinical resemblance of heparin-induced thrombocytopenia

Literature - Apr. 6, 2021 - Greinacher A et al. - Research Square 2021 (NOT PEER-REVIEWED)

Some cases of thrombotic events combined with thrombocytopenia have been described after COVID-19 vaccination with AZD1222. This thrombotic disorder clinically resembles heparin-induced thrombocytopenia, with a different serological profile.

High incidence of thrombotic complications in first and second COVID-19 wave

5' education - Mar. 5, 2021 - Fleur Kaptein, MD
Incidence of thrombotic complications remained high in hospitalized COVID-19 patients in the second wave. Thromboprophylaxis is therefore warranted in these patients.

Incidence of thrombotic complications remained high in hospitalized COVID-19 patients in the second wave. Thromboprophylaxis is therefore warranted in these patients.

Incidence of thrombotic complications in hospitalized COVID-19 patients remained high in second wave

Literature - Mar. 5, 2021 - Kaptein FHJ et al., - Thrombosis Research 2020.

Risk of overall mortality in COVID-19 patients was lower in the second wave, compared with the first wave. However, cumulative incidences of thrombotic complications remained high in the second wave.

During COVID-19 pandemic, lower rate of cholesterol testing

Literature - Mar. 5, 2021 - Gumuser ED, et al. - Am J Prev Cardiol 2021
Compared to the same period in 2019, cholesterol testing rate was almost 40% lower between March-September 2020 when analyzing data from a healthcare system in New England, USA.

Compared to the same period in 2019, cholesterol testing rate was almost 40% lower between March-September 2020 when analyzing data from a healthcare system in New England, USA.

COVID-19